Accessibility Menu
Argenx Se logo

Argenx Se(NASDAQ) ARGX

Market Cap$64.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+4,217%
5 Year+228%
1 Year+57%
1 Month+22%
$1,035.40
+0.25%
+2.54Today
Argenx Se last closing stock price
MetricPriceDate
Last closeUSD 1,032.862026-08-19
Argenx Se stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+17.91%USD 876.002026-08-12
1 month+22.06%USD 846.192026-07-20
3 month+26.54%USD 816.222026-05-21
Year to date+22.82%USD 840.952025-12-31
1 year+57.23%USD 656.892025-08-19
3 year+111.4%USD 488.592023-08-18
5 year+228.33%USD 314.582021-08-20
Since inception+4,217.35%USD 23.002017-05-18

Argenx Se Financials at a Glance

Market Cap

$64.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.76B

Net Income (TTM)

$2.30B

EPS (TTM)

$26.24

P/E Ratio

37.24

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$1,035.40

Volume

73,865.574

Open

$1,019.16

Previous Close

$1,032.86

Daily Range

$1,018.98 - $1,034.42

52-Week Range

$658.60 - $1,035.09

Estimated Earnings Date

Mar 4, 2027

ARGX News

A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsJul 10, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

How to Invest in iShares Biotechnology ETF (IBB)

Tony DongFeb 25, 2026
Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in VanEck Biotech ETF (BBH)

Tony DongFeb 25, 2026
Doctor and patient in a hospital room

Is Argenx Stock a Buy Now?

Prosper Junior BakinyJul 31, 2023
healthcare lab treatment research scientist

Why Shares of Argenx Jumped This Week

James HalleyJul 21, 2023
young-woman-holding-thumbs-up

Why Argenx Stock Is on Fire Today

George Budwell, PhDJul 17, 2023
Biotech GettyImages-1215565992

You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers

Dan CaplingerJul 17, 2023
Female scientist observing with microscope

This Emerging Market Could Be the Next Big Thing in Biotech

Alex CarchidiJul 14, 2023
Page 1

ARGX: Motley Fool Moneyball Superscore

89

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Argenx Se

argenx SE is a biotechnology company based in Amsterdam, dedicated to developing innovative therapies for autoimmune diseases. Established in 2008, the company operates in key global markets, including the United States, Europe, and Asia, with a focus on addressing a wide range of conditions through its leading investigational therapy, efgartigimod.

Products and Services
  • efgartigimod for various autoimmune diseases
  • Extensive pipeline including ARGX-119 and ARGX-213
  • Proprietary products like VYVGART and VYVGART HYTRULO
Growth Outlook
  • Recent quarterly revenue reached $2.82 billion, showcasing strong market demand
  • TTM net income margin stands at 32.87%, indicating robust profitability
  • Strategic collaborations with major partners enhance development capabilities
Financial Highlights
  • Cash and short-term investments total $5.18 billion, providing strong liquidity
  • Operating income for Q2 2026 was $846.83 million, reflecting operational efficiency
  • Net income for Q2 2026 reached $838.82 million, demonstrating significant growth
AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,863

CEO

Tim van Hauwermeiren, EMBA

Website

www.argen-x.com

Headquarters

Amsterdam, NH 1101 EB, NL

ARGX Financials

Key Financial Metrics (TTM)

Gross Margin

89.94%

Operating Margin

28.81%

Net Income Margin

32.87%

Return on Equity

21.66%

Return on Capital

14.24%

Return on Assets

16.99%

Earnings Yield

2.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$64.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.56M

Volume

73.87K

Avg. Volume

334.76K

Financials (TTM)

Gross Profit

$6.95B

Operating Income

$2.04B

EBITDA

$2.36B

Operating Cash Flow

$1.64B

Capital Expenditure

-$10.14M

Free Cash Flow

$1.63B

Cash & ST Invst.

$5.18B

Total Debt

$47.00M

Argenx Se Performance Analysis

Argenx Se annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 410,970,991-17.2%
20232023-12-31USD 1,228,215,279198.9%
20242024-12-31USD 2,186,362,05978.0%
20252025-12-31USD 4,166,333,71790.6%
Argenx Se sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-41.3%
Q22025-06-3019.9%
Q42025-12-31N/A
Q22026-06-30N/A
Argenx Se annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -13.0663.6%
20232023-12-31USD -5.17-60.4%
20242024-12-31USD 12.76N/A
20252025-12-31USD 19.6353.8%
Argenx Se sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30146.9%
Q42025-12-31N/A
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.82B

+109.2%

Gross Profit

$2.54B

+272.3%

Gross Margin

90.08%

N/A

Market Cap

$64.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$34.68M

N/A

Employees

1,863

N/A

Net Income

$838.82M

-3.1%

EBITDA

$863.85M

+582.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.18B

+67.1%

Total Debt

$47.00M

+38.4%

Accounts Receivable

$1.94B

+196.1%

Inventory

$371.00M

+13.6%

Long Term Debt

$36.00M

+28.1%

Short Term Debt

$11.00M

+87.9%

Return on Assets

16.99%

N/A

Return on Invested Capital

17.67%

N/A

Free Cash Flow

$748.74M

+696.8%

Operating Cash Flow

$751.74M

+703.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAHCardinal Health, Inc.
$231.77-1.31%
EWEdwards Lifesciences Corporation
$91.45-0.90%
BDXBecton, Dickinson and Company
$189.45+0.98%
AAgilent Technologies, Inc.
$158.85+2.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$40.71+0.05%
BITOProShares Trust - ProShares Bitcoin ETF
$9.72+0.05%
SPCXSpace Exploration Technologies
$132.94-0.05%
MRNAModerna
$139.72-0.20%

Questions About ARGX

What is the current price of Argenx Se?

Argenx Se is trading at $1,031.23 per share.

What is the 52-week range for Argenx Se?

Over the past 52 weeks, Argenx Se has traded between $658.60 and $1,035.09.

How much debt does Argenx Se have?

As of the most recent reporting period, Argenx Se reported total debt of $47.16M.

How much cash does Argenx Se have on hand?

Argenx Se reported $3.49B in cash and cash equivalents in its most recent financial results.

What is Argenx Se’s dividend yield?

Argenx Se does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services